Evidence map›Paper›PMID 24590932›Full record

ArticleHealth affairs (Project Hope)2014

Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996-2009.

Dana P Goldman, Timothy Juday, Daniel Seekins, Mark T Linthicum, John A Romley

Abstract read
In one paragraph

Article in Health affairs (Project Hope), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Impact of Depression and Inflammation on the Progression of HIV Disease.Journal of clinical & cellular immunology · 2016
    Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 3 countries.

Dana P Goldman
Timothy Juday
Daniel Seekins
Mark T Linthicum
John A Romley
Bristol-Myers Squibb (Germany) · DEGoldman Sachs (United States) · USHealth Economics and Outcomes Research (United Kingdom) · GBPrecision for Medicine (United States) · USUniversity of Southern California · US

Funding

ECONOMICS OF TREATING VIRAL STIsR01HD054877 · NICHD · RAND CORPORATION · PI GOLDMAN, DANA P · 2009 to 2010
$985k
NICHD NIH HHS 5R01HD054877NICHD NIH HHS R01 HD054877
6 · The paper itself

Abstract

In recent years, guidelines for HIV treatment have recommended initiation of combination antiretroviral therapy (cART) earlier in the course of the disease than was previously the case. These recommendations stem in part from growing evidence that treatment reduces the risk of sexual transmission. We used an epidemiological model of disease transmission and progression to assess HIV prevention through early treatment-that is, initiation of cART when CD4 white blood cell counts are in excess of 350 cells per cubic millimeter. (CD4 cells are involved in the immune system's defense against tumors and infection; the number of CD4 cells in a cubic millimeter of blood is a standard measure of immune response to antiretroviral therapy.) We estimated that the actual timing of treatment initiation in the United States prevented 188,000 HIV cases in the period 1996-2009. "Very early" treatment (at CD4 counts greater than 500) accounted for four-fifths of the prevented cases. For all of the prevented cases, the losses in life expectancy that were avoided were worth $128 billion, assuming that a life-year has a value of $150,000. These findings underscore the cost-effectiveness of early HIV treatment.

Indexed as

Early Medical InterventionAnti-HIV AgentsCD4 Lymphocyte CountCost-Benefit AnalysisCross-Sectional StudiesDrug Therapy, CombinationEvidence-Based MedicineHIV InfectionsHumansIncidenceLife ExpectancySurvival AnalysisUnited StatesValue of LifeAnti-HIV AgentsAIDS/HIVConsumer IssuesHealth Promotion/Disease PreventionHealth ReformPublic Health

Identifiers

PMID24590932
PMCPMC4124881
OpenAlexW2071411286

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.